Zydus Lifesciences, a company owned by Pankaj Patel, is also involved in the production of the ZyCoV-D vaccine used for preventing Covid-19.
India is renowned for its pharmaceutical industry, which produces a significant amount of drugs for both domestic and international markets. The Indian pharma sector is projected to continue growing in the coming years, with several prominent players in the market. Among these is Zydus Lifesciences, a multinational pharmaceutical company led by Pankaj Patel, a prominent figure in the pharma industry. Patel’s company is responsible for manufacturing the Covid-19 vaccine ZyCoV-D. In this article, we will explore more about Pankaj Patel and his impressive career in the Indian pharma sector.
Pankaj Patel, hailing from Gujarat, is an Indian billionaire businessman and the current chairman of Zydus Lifesciences, previously known as Cadila Healthcare Ltd. He obtained his Bachelor of Pharmacy and Master of Pharmacy degrees from Gujarat University.
Also Read: Meet Shaheen Bhatt, The Bollywood Star’s Sister Who Has Been Gifted 2 Flats Worth Rs 45.6 Crore
As per Forbes, Pankaj Patel’s net worth is estimated at $5.2 billion (Rs. 42,610 crore) as of April 25, 2023, making him one of the richest people in India. Currently, he is ranked 524th among the world’s wealthiest individuals. In 2022, he held the 49th spot on India’s richest list. Patel’s company, Zydus Lifesciences Limited, is headquartered in Ahmedabad and currently has a market capitalization of approximately Rs. 52,400 crores.
Priti Patel is Patel’s spouse, and the couple has two children. Their son, Dr Sharvil Patel, is currently serving as the managing director of Zydus. Their daughter, Shivani, is married to Pranav D Patel.
According to the Zydus website, Patel is a board member of various institutions, such as the chairperson of the Board of Governors of IIM Ahmedabad and Invest India, and the chairman of IIM Udaipur. He has authored over 100 research papers in peer-reviewed journals and has co-invented more than 64 patents.
